

**UNITED STATES OF AMERICA**  
**Before the**  
**SECURITIES AND EXCHANGE COMMISSION**

**April 23, 2020**

**In the Matter of**

**Decision Diagnostics Corp.**

**File No. 500-1**

**ORDER OF SUSPENSION OF  
TRADING**

It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Decision Diagnostics Corp. (“DECN” or “the Company”) (CIK No. 0001144225) because of questions regarding the accuracy and adequacy of information in the marketplace since at least March 3, 2020. Those questions relate to DECN’s press releases, among other things, (i) claiming to have “technology perfected” to allow it to manufacture and sell a COVID-19 test kit that would provide results “in 15 seconds, based on a small finger prick blood sample,” and (ii) issuing sales forecasts that up to 525 million COVID 19 test kits would be sold in the first year of production. The Company’s common stock is quoted on OTC Link (previously Pink Sheets), operated by OTC Markets Group Inc., under the symbol DECN. As of April 21, 2020, DECN’s common stock has 13 market makers, and the issuer’s common stock is eligible for the “piggyback” exception of Rule 15c2-11(f)(3) under the Securities Exchange Act of 1934.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed company is suspended for the period from 9:30 a.m. EDT on April 24, 2020, through 11:59 p.m. EDT on May 7, 2020.

By the Commission.

Vanessa A. Countryman  
Secretary